Valuation Update With 7 Day Price Move • May 21
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to ₩293,500, the stock trades at a forward P/E ratio of 15x. Average forward P/E is 17x in the Biotechs industry in South Korea. Total returns to shareholders of 165% over the past three years. Price Target Changed • May 11
Price target decreased by 7.4% to ₩520,500 Down from ₩561,800, the current price target is an average from 14 analysts. New target price is 59% above last closing price of ₩328,000. Stock is down 18% over the past year. The company is forecast to post earnings per share of ₩19,169 for next year compared to ₩15,893 last year. Price Target Changed • May 01
Price target decreased by 8.0% to ₩538,357 Down from ₩585,214, the current price target is an average from 14 analysts. New target price is 72% above last closing price of ₩313,500. Stock is down 20% over the past year. The company is forecast to post earnings per share of ₩19,870 for next year compared to ₩15,893 last year. Announcement • Apr 29
PharmaResearch Co., Ltd. to Report Q1, 2026 Results on May 08, 2026 PharmaResearch Co., Ltd. announced that they will report Q1, 2026 results on May 08, 2026 New Risk • Mar 29
New minor risk - Dividend sustainability The company has an unstable dividend paying track record. The dividend has had an annual drop of over 20% in the past. Dividend yield: 1.2% This is considered a minor risk. If the company has cut or reduced its dividend in the past, it may be a sign that the underlying business is too cyclical to consistently maintain or grow the dividend over the long-term. It may also indicate the company prioritizes other outcomes instead of maintaining the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. This is currently the only risk that has been identified for the company. Reported Earnings • Mar 25
Full year 2025 earnings: EPS and revenues miss analyst expectations Full year 2025 results: EPS: ₩15,893 (up from ₩8,941 in FY 2024). Revenue: ₩536.3b (up 53% from FY 2024). Net income: ₩165.1b (up 79% from FY 2024). Profit margin: 31% (up from 26% in FY 2024). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 2.1%. Earnings per share (EPS) also missed analyst estimates by 14%. Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in South Korea. Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has increased by 67% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Mar 10
PharmaResearch Co., Ltd., Annual General Meeting, Mar 27, 2026 PharmaResearch Co., Ltd., Annual General Meeting, Mar 27, 2026, at 11:00 Tokyo Standard Time. Location: conference room, 77-19, gwahakdanji-ro, gangwon-do, gangreung South Korea Valuation Update With 7 Day Price Move • Mar 04
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to ₩288,000, the stock trades at a forward P/E ratio of 15x. Average trailing P/E is 24x in the Biotechs industry in South Korea. Total returns to shareholders of 303% over the past three years. Price Target Changed • Feb 09
Price target decreased by 11% to ₩646,385 Down from ₩724,846, the current price target is an average from 13 analysts. New target price is 92% above last closing price of ₩337,000. Stock is up 23% over the past year. The company is forecast to post earnings per share of ₩17,357 for next year compared to ₩8,941 last year. Announcement • Feb 06
PharmaResearch Co., Ltd. Receives U.S. FDA Clearance to Initiate Phase 1 Clinical Trial of Nano Anticancer Drug, PRD-101 PharmaResearch Co., Ltd. announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for PRD-101, enabling the initiation of a Phase 1 clinical trial in the United States. PRD-101 is a next-generation nano anticancer drug candidate formulated using nucleotide fragments produced through PharmaResearch's proprietary DOT®? (DNA Optimizing Technology). The drug leverages the company's nucleotide-based Advanced DOT™? drug delivery platform, designed to enable efficient loading of therapeutics and improve pharmacokinetics. The Phase 1 clinical trial will be conducted across up to seven clinical sites in the United States and is expected to enroll approximately 90 patients with locally advanced or metastatic solid tumors. The study is designed to evaluate the safety, tolerability, and pharmacokinetics of PRD-101. PRD-101 represents a significant advancement in cancer treatment, utilizing nucleotide fragments produced through Pharma Research's proprietary DNA optimizing technology (DOT®?) in nanoparticle anticancer formulations. Collaborative efforts between PharmaResearch and the University of California Irvine (UCI) researchers, along with support from organizations like the U.S.NCL, have propelled the development of PRD-101. PharmaResearch holds patents and exclusive licenses associated with PRD-101, marking a milestone in the company's innovative edges. Traditional anticancer drugs often face limitations due to high toxicity, which restricts patient eligibility and necessitates careful dosage management. PharmaResearch anticipates that PRD-101 will address these unmet medical needs in anticancer therapy. Announcement • Jan 28
PharmaResearch Co., Ltd. to Report Q4, 2025 Results on Feb 09, 2026 PharmaResearch Co., Ltd. announced that they will report Q4, 2025 results on Feb 09, 2026 Valuation Update With 7 Day Price Move • Jan 26
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to ₩501,000, the stock trades at a forward P/E ratio of 24x. Average forward P/E is 18x in the Biotechs industry in South Korea. Total returns to shareholders of 583% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩851,965 per share. Upcoming Dividend • Dec 22
Upcoming dividend of ₩1,100 per share Eligible shareholders must have bought the stock before 29 December 2025. Payment date: 17 April 2026. Payout ratio is a comfortable 7.6% and this is well supported by cash flows. Trailing yield: 0.3%. Lower than top quartile of South Korean dividend payers (3.6%). Lower than average of industry peers (0.6%). Price Target Changed • Nov 14
Price target decreased by 7.5% to ₩738,333 Down from ₩798,333, the current price target is an average from 12 analysts. New target price is 63% above last closing price of ₩452,000. Stock is up 106% over the past year. The company is forecast to post earnings per share of ₩17,516 for next year compared to ₩8,941 last year. Valuation Update With 7 Day Price Move • Nov 11
Investor sentiment deteriorates as stock falls 18% After last week's 18% share price decline to ₩440,000, the stock trades at a forward P/E ratio of 22x. Average forward P/E is 19x in the Biotechs industry in South Korea. Total returns to shareholders of 603% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩874,309 per share. Declared Dividend • Nov 08
Dividend of ₩1,100 announced Dividend of ₩1,100 is the same as last year. Ex-date: 29th December 2025 Payment date: 17th April 2026 Dividend yield will be 0.2%, which is lower than the industry average of 0.5%. Payout Ratios Payout ratio: 9%. Cash payout ratio: 10%. Announcement • Nov 07
PharmaResearch Co., Ltd. announces Annual dividend, payable on April 17, 2026 PharmaResearch Co., Ltd. announced Annual dividend of KRW 1100.0000 per share payable on April 17, 2026, ex-date on December 29, 2025 and record date on December 31, 2025. Announcement • Oct 28
BioNote, Inc. (KOSE:A377740) completed the acquisition of an additional 10.6% stake in CTCBIO Inc. (KOSDAQ:A060590) from PharmaResearch Co., Ltd. (KOSDAQ:A214450). BioNote, Inc. (KOSE:A377740) signed a stock transfer agreement to acquire an additional 10.6% stake in CTCBIO Inc. (KOSDAQ:A060590) from PharmaResearch Co., Ltd. (KOSDAQ:A214450) for KRW 21.9 billion on September 26, 2025. A cash consideration of KRW 21.88 billion valued at KRW 8532 per share will be paid by BioNote, Inc. As part of consideration, KRW 21.88 billion is paid towards common equity of CTCBIO Inc.
The expected completion of the transaction is December 24, 2025.
BioNote, Inc. (KOSE:A377740) completed the acquisition of an additional 10.6% stake in CTCBIO Inc. (KOSDAQ:A060590) from PharmaResearch Co., Ltd. (KOSDAQ:A214450) on October 27, 2025. On completion, BioNote, Inc. and PharmaResearch Co., Ltd. will own 23.04% and 10.61% stake respectively in CTCBIO Inc. Major Estimate Revision • Aug 13
Consensus EPS estimates increase by 11% The consensus outlook for earnings per share (EPS) in fiscal year 2025 has improved. 2025 revenue forecast increased from ₩530.0m to ₩566.1m. EPS estimate increased from ₩15,501 to ₩17,222 per share. Net income forecast to grow 76% next year vs 42% growth forecast for Biotechs industry in South Korea. Consensus price target up from ₩657,000 to ₩746,364. Share price rose 11% to ₩665,000 over the past week. Valuation Update With 7 Day Price Move • Aug 08
Investor sentiment improves as stock rises 21% After last week's 21% share price gain to ₩664,000, the stock trades at a forward P/E ratio of 40x. Average forward P/E is 26x in the Biotechs industry in South Korea. Total returns to shareholders of 884% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩916,253 per share. Announcement • Aug 02
PharmaResearch Co., Ltd. to Report First Half, 2025 Results on Aug 08, 2025 PharmaResearch Co., Ltd. announced that they will report first half, 2025 results on Aug 08, 2025 Buy Or Sell Opportunity • Jul 10
Now 23% undervalued Over the last 90 days, the stock has risen 53% to ₩561,000. The fair value is estimated to be ₩729,309, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 28% over the last 3 years. Earnings per share has grown by 33%. Revenue is forecast to grow by 76% in 2 years. Earnings are forecast to grow by 87% in the next 2 years. New Risk • Jul 08
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Valuation Update With 7 Day Price Move • Jul 08
Investor sentiment improves as stock rises 23% After last week's 23% share price gain to ₩588,000, the stock trades at a forward P/E ratio of 38x. Average forward P/E is 33x in the Biotechs industry in South Korea. Total returns to shareholders of 867% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩729,309 per share. Major Estimate Revision • Jun 18
Consensus EPS estimates increase by 12%, revenue downgraded The consensus outlook for fiscal year 2025 has been updated. 2025 revenue forecast fell from ₩504.1m to ₩498.6m. EPS estimate rose from ₩12,539 to ₩14,024. Net income forecast to grow 44% next year vs 44% growth forecast for Biotechs industry in South Korea. Consensus price target broadly unchanged at ₩454,091. Share price fell 17% to ₩432,000 over the past week. Valuation Update With 7 Day Price Move • Jun 17
Investor sentiment deteriorates as stock falls 19% After last week's 19% share price decline to ₩420,000, the stock trades at a forward P/E ratio of 29x. Average forward P/E is 29x in the Biotechs industry in South Korea. Total returns to shareholders of 490% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩703,512 per share. Buy Or Sell Opportunity • Jun 13
Now 27% undervalued Over the last 90 days, the stock has risen 29% to ₩433,500. The fair value is estimated to be ₩596,089, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 28% over the last 3 years. Earnings per share has grown by 33%. Revenue is forecast to grow by 66% in 2 years. Earnings are forecast to grow by 78% in the next 2 years. Major Estimate Revision • May 22
Consensus revenue estimates increase by 11%, EPS downgraded The consensus outlook for fiscal year 2025 has been updated. 2025 revenue forecast increased from ₩448.6m to ₩495.8m. EPS estimate fell from ₩12,697 to ₩12,539. Net income forecast to grow 60% next year vs 34% growth forecast for Biotechs industry in South Korea. Consensus price target up from ₩352,300 to ₩449,364. Share price rose 7.4% to ₩440,500 over the past week. Price Target Changed • May 15
Price target increased by 18% to ₩415,300 Up from ₩352,300, the current price target is an average from 10 analysts. New target price is approximately in line with last closing price of ₩410,000. Stock is up 199% over the past year. The company is forecast to post earnings per share of ₩13,499 for next year compared to ₩8,941 last year. Valuation Update With 7 Day Price Move • Apr 14
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₩366,000, the stock trades at a forward P/E ratio of 29x. Average forward P/E is 27x in the Biotechs industry in South Korea. Total returns to shareholders of 287% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩405,278 per share. Buy Or Sell Opportunity • Mar 25
Now 20% undervalued Over the last 90 days, the stock has risen 20% to ₩319,500. The fair value is estimated to be ₩400,041, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 27% over the last 3 years. Earnings per share has grown by 29%. Revenue is forecast to grow by 51% in 2 years. Earnings are forecast to grow by 74% in the next 2 years. Reported Earnings • Mar 21
Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind Full year 2024 results: EPS: ₩8,941 (up from ₩7,571 in FY 2023). Revenue: ₩350.1b (up 34% from FY 2023). Net income: ₩92.0b (up 20% from FY 2023). Profit margin: 26% (down from 29% in FY 2023). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 2.4%. Earnings per share (EPS) missed analyst estimates by 8.0%. Revenue is forecast to grow 20% p.a. on average during the next 2 years, compared to a 35% growth forecast for the Biotechs industry in South Korea. Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has increased by 53% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Mar 12
PharmaResearch Co., Ltd., Annual General Meeting, Mar 25, 2025 PharmaResearch Co., Ltd., Annual General Meeting, Mar 25, 2025, at 11:00 Tokyo Standard Time. Location: conference room, 77-19, gwahakdanji-ro, gangwon-do, gangreung South Korea Announcement • Mar 11
PharmaResearch Co., Ltd. announces Annual dividend, payable on April 17, 2025 PharmaResearch Co., Ltd. announced Annual dividend of KRW 1100.0000 per share payable on April 17, 2025, ex-date on December 27, 2024 and record date on December 31, 2024. Buy Or Sell Opportunity • Mar 07
Now 23% undervalued Over the last 90 days, the stock has risen 43% to ₩305,000. The fair value is estimated to be ₩398,080, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 26% over the last 3 years. Earnings per share has grown by 27%. Revenue is forecast to grow by 60% in 2 years. Earnings are forecast to grow by 76% in the next 2 years. Price Target Changed • Feb 15
Price target increased by 7.5% to ₩307,875 Up from ₩286,500, the current price target is an average from 8 analysts. New target price is 7.5% above last closing price of ₩286,500. Stock is up 197% over the past year. The company is forecast to post earnings per share of ₩9,717 for next year compared to ₩7,571 last year. Price Target Changed • Feb 11
Price target increased by 7.6% to ₩304,125 Up from ₩282,750, the current price target is an average from 8 analysts. New target price is 6.9% above last closing price of ₩284,500. Stock is up 193% over the past year. The company is forecast to post earnings per share of ₩9,717 for next year compared to ₩7,571 last year. Valuation Update With 7 Day Price Move • Dec 16
Investor sentiment improves as stock rises 21% After last week's 21% share price gain to ₩256,000, the stock trades at a forward P/E ratio of 22x. Average forward P/E is 28x in the Biotechs industry in South Korea. Total returns to shareholders of 241% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩423,825 per share. Price Target Changed • Nov 16
Price target increased by 8.7% to ₩276,000 Up from ₩253,857, the current price target is an average from 7 analysts. New target price is 26% above last closing price of ₩219,000. Stock is up 90% over the past year. The company is forecast to post earnings per share of ₩9,828 for next year compared to ₩7,571 last year. New Risk • Jun 03
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (8.0% average weekly change). Shareholders have been diluted in the past year (2.1% increase in shares outstanding). New Risk • Jun 01
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.1% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. This is currently the only risk that has been identified for the company. Price Target Changed • May 28
Price target increased by 7.1% to ₩187,500 Up from ₩175,000, the current price target is an average from 4 analysts. New target price is 37% above last closing price of ₩136,400. Stock is up 20% over the past year. The company is forecast to post earnings per share of ₩9,486 for next year compared to ₩7,571 last year. Valuation Update With 7 Day Price Move • May 03
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to ₩139,600, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 22x in the Biotechs industry in South Korea. Total returns to shareholders of 106% over the past three years. Reported Earnings • Mar 20
Full year 2023 earnings released: EPS: ₩7,571 (vs ₩4,067 in FY 2022) Full year 2023 results: EPS: ₩7,571 (up from ₩4,067 in FY 2022). Revenue: ₩261.0b (up 34% from FY 2022). Net income: ₩76.6b (up 89% from FY 2022). Profit margin: 29% (up from 21% in FY 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 14% p.a. on average during the next 2 years, compared to a 18% growth forecast for the Biotechs industry in South Korea. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has only increased by 10% per year, which means it is significantly lagging earnings growth. Upcoming Dividend • Dec 20
Upcoming dividend of ₩660 per share at 0.6% yield Eligible shareholders must have bought the stock before 27 December 2023. Payment date: 15 April 2024. Payout ratio is a comfortable 10% and this is well supported by cash flows. Trailing yield: 0.6%. Lower than top quartile of South Korean dividend payers (3.5%). In line with average of industry peers (0.7%). Price Target Changed • Aug 15
Price target increased by 19% to ₩158,750 Up from ₩133,000, the current price target is an average from 4 analysts. New target price is 8.1% above last closing price of ₩146,900. Stock is up 106% over the past year. The company is forecast to post earnings per share of ₩7,083 for next year compared to ₩4,067 last year. Valuation Update With 7 Day Price Move • Aug 10
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to ₩154,400, the stock trades at a forward P/E ratio of 21x. Average forward P/E is 38x in the Biotechs industry in South Korea. Total returns to shareholders of 161% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩199,306 per share. Buying Opportunity • Aug 02
Now 20% undervalued Over the last 90 days, the stock is up 32%. The fair value is estimated to be ₩167,456, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 29% over the last 3 years. Earnings per share has grown by 21%. Revenue is forecast to grow by 41% in 2 years. Earnings is forecast to grow by 74% in the next 2 years. New Risk • Jul 12
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.0% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. This is currently the only risk that has been identified for the company. Buying Opportunity • May 24
Now 20% undervalued Over the last 90 days, the stock is up 56%. The fair value is estimated to be ₩145,114, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 30% over the last 3 years. Earnings per share has grown by 26%. For the next 3 years, revenue is forecast to grow by 16% per annum. Earnings is also forecast to grow by 22% per annum over the same time period. Price Target Changed • May 18
Price target increased by 11% to ₩107,500 Up from ₩96,500, the current price target is an average from 4 analysts. New target price is 9.4% below last closing price of ₩118,700. Stock is up 50% over the past year. The company is forecast to post earnings per share of ₩6,119 for next year compared to ₩4,067 last year. Valuation Update With 7 Day Price Move • May 17
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to ₩118,700, the stock trades at a forward P/E ratio of 19x. Average forward P/E is 20x in the Biotechs industry in South Korea. Total returns to shareholders of 124% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩81,883 per share. Valuation Update With 7 Day Price Move • Apr 18
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₩103,100, the stock trades at a forward P/E ratio of 17x. Average forward P/E is 25x in the Biotechs industry in South Korea. Total returns to shareholders of 163% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩83,177 per share. Valuation Update With 7 Day Price Move • Apr 04
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to ₩83,700, the stock trades at a forward P/E ratio of 13x. Average forward P/E is 22x in the Biotechs industry in South Korea. Total returns to shareholders of 107% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩93,560 per share. Buying Opportunity • Feb 24
Now 21% undervalued Over the last 90 days, the stock is up 12%. The fair value is estimated to be ₩92,114, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 30% over the last 3 years. Earnings per share has grown by 32%. For the next 3 years, revenue is forecast to grow by 14% per annum. Earnings is also forecast to grow by 17% per annum over the same time period. Price Target Changed • Jan 11
Price target decreased to ₩88,300 Down from ₩96,500, the current price target is an average from 3 analysts. New target price is 29% above last closing price of ₩68,400. Stock is down 14% over the past year. The company is forecast to post earnings per share of ₩5,252 for next year compared to ₩4,717 last year. Upcoming Dividend • Dec 21
Upcoming dividend of ₩600 per share Eligible shareholders must have bought the stock before 28 December 2022. Payment date: 20 April 2023. Payout ratio is a comfortable 13% and this is well supported by cash flows. Trailing yield: 0.9%. Lower than top quartile of South Korean dividend payers (3.3%). Higher than average of industry peers (0.7%). Major Estimate Revision • Nov 17
Consensus forecasts updated The consensus outlook for 2022 has been updated. 2022 revenue forecast fell from ₩195.4m to ₩192.4m. EPS estimate rose from ₩4,774 to ₩5,393. Net income forecast to grow 43% next year vs 26% growth forecast for Biotechs industry in South Korea. Consensus price target of ₩96,500 unchanged from last update. Share price was steady at ₩64,700 over the past week. Price Target Changed • Nov 16
Price target decreased to ₩96,500 Down from ₩112,500, the current price target is an average from 4 analysts. New target price is 48% above last closing price of ₩65,000. Stock is down 18% over the past year. The company is forecast to post earnings per share of ₩4,774 for next year compared to ₩4,717 last year. Price Target Changed • Sep 16
Price target decreased to ₩100,000 Down from ₩112,500, the current price target is an average from 4 analysts. New target price is 60% above last closing price of ₩62,400. Stock is down 32% over the past year. The company is forecast to post earnings per share of ₩4,642 for next year compared to ₩4,717 last year. Major Estimate Revision • May 31
Consensus forecasts updated The consensus outlook for 2022 has been updated. 2022 EPS estimate fell from ₩5,701 to ₩4,891 per share. Revenue forecast steady at ₩184.0m. Net income forecast to grow 20% next year vs 22% growth forecast for Biotechs industry in South Korea. Consensus price target down from ₩112,500 to ₩105,000. Share price rose 3.9% to ₩82,700 over the past week. Price Target Changed • Apr 27
Price target increased to ₩112,500 Up from ₩104,500, the current price target is an average from 4 analysts. New target price is 21% above last closing price of ₩93,100. Stock is up 27% over the past year. The company is forecast to post earnings per share of ₩5,701 for next year compared to ₩4,717 last year. Upcoming Dividend • Dec 22
Upcoming dividend of ₩500 per share Eligible shareholders must have bought the stock before 29 December 2021. Payment date: 15 April 2022. Payout ratio is a comfortable 10% and this is well supported by cash flows. Trailing yield: 0.6%. Lower than top quartile of South Korean dividend payers (2.4%). Lower than average of industry peers (0.8%). Announcement • Nov 25
PharmaResearch Co., Ltd. (KOSDAQ:A214450) acquired Medicoson Co., Ltd. PharmaResearch Co., Ltd. (KOSDAQ:A214450) acquired Medicoson Co., Ltd. on November 24, 2021.
PharmaResearch Co., Ltd. (KOSDAQ:A214450) completed the acquisition of Medicoson Co., Ltd. on November 24, 2021. Price Target Changed • Aug 24
Price target increased to ₩120,000 Up from ₩104,500, the current price target is an average from 4 analysts. New target price is 22% above last closing price of ₩98,700. Stock is up 40% over the past year. Major Estimate Revision • Aug 19
Consensus revenue estimates increase to ₩152.8m The consensus outlook for revenues in 2021 has improved. 2021 revenue forecast increased from ₩137.2m to ₩152.8m. EPS estimate increased from ₩4,345 to ₩4,667 per share. Net income forecast to grow 21% next year vs 21% growth forecast for Biotechs industry in South Korea. Consensus price target up from ₩104,500 to ₩109,500. Share price fell 3.4% to ₩93,600 over the past week. Price Target Changed • May 20
Price target increased to ₩88,100 Up from ₩78,433, the current price target is an average from 3 analysts. New target price is 10.0% above last closing price of ₩80,100. Stock is up 48% over the past year. Is New 90 Day High Low • Feb 01
New 90-day high: ₩64,900 The company is up 6.0% from its price of ₩61,500 on 03 November 2020. The South Korean market is up 27% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 16% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ₩114,878 per share. Is New 90 Day High Low • Jan 08
New 90-day low: ₩53,900 The company is down 14% from its price of ₩63,000 on 08 October 2020. The South Korean market is up 25% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 22% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ₩115,644 per share. Is New 90 Day High Low • Dec 22
New 90-day low: ₩56,100 The company is down 12% from its price of ₩63,800 on 23 September 2020. The South Korean market is up 18% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 14% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ₩115,713 per share. Is New 90 Day High Low • Dec 02
New 90-day low: ₩57,600 The company is down 21% from its price of ₩73,100 on 03 September 2020. The South Korean market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ₩103,912 per share. Reported Earnings • Nov 15
Third quarter 2020 earnings released: EPS ₩812 The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2020 results: Revenue: ₩29.1b (up 49% from 3Q 2019). Net income: ₩7.71b (up 102% from 3Q 2019). Profit margin: 27% (up from 20% in 3Q 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth. Price Target Changed • Nov 10
Price target raised to ₩78,433 Up from ₩67,233, the current price target is an average from 4 analysts. The new target price is 26% above the current share price of ₩62,200. As of last close, the stock is up 78% over the past year. 
